Currently, diagnosis of glaucoma and patient management decisions are often informed by thinning of the
optic nerve head (ONH) neuro-retinal rim, peripapillary retinal nerve fiber layer (RNFL), and macular inner
retinal layers, as detected using optical coherence tomography (OCT). These measurements are useful
because they are predictive of subsequent visual field decline, and of faster rates of subsequent thinning.
However, by the time thinning can be detected with current OCT systems, retinal ganglion cells (RGCs) and
their axons have already been lost, and therefore some impairment of visual function is unavoidable. Thus, a
key gap in the current approach to glaucoma care is the lack of reliable biomarkers that alert the clinician to
early-stage glaucomatous damage of RGCs/axons before they are permanently lost. We propose that such
information is present within OCT scans from commercially available instruments, but that additional
approaches for testing and analysis are required to reveal this information. Our overarching hypothesis is
that cues of eye-specific sensitivity to intraocular pressure (IOP) and early RGC/axon distress and
damage are present in OCT scans, and that exploiting them will provide meaningful clinical benefits.
We will use a well-established non-human primate (NHP) model of experimental glaucoma to test three
independent, but mutually supportive, hypotheses, each with its own strong potential to advance clinical care
and patient management. In Aim 1, we will test the hypothesis that larger magnitude deformations within the
ONH rim and peripapillary RNFL tissues will predict earlier and more severe loss of RGCs/axons across eyes
and locations (sectors). Specifically, in Aim 1.1, we test this prediction using the deformations resulting from
acute IOP elevation (i.e., elastic deformations or strains), and in Aim 1.2, using the deformations measured
after exposure to chronic IOP elevation (plastic deformations and remodeling). In Aim 2, we will test the
hypothesis that autoregulation dysfunction within the ONH and peripapillary RNFL tissues precedes capillary
dropout (Aim 2.1) and precedes RGCs/axon loss (Aim 2.2). In Aim 3, we will test the hypothesis that an early
stage of RGC pathology, characterized by disruption of axonal cytoskeletal ultrastructure and dendritic atrophy,
is detectable by OCT (Aim 3.1); that its onset and location are predicted by the acute and chronic deformations
determined by strain mapping (Aim 3.2); and that it represents a sign of imminent loss of RGCs/axons (Aim
3.3). Success of any one Aim would represent an important step forward in the determination of risk for
glaucoma progression in individual eyes; success of all three Aims would represent a major step forward in this
area as each biomarker could enhance the predictive capacity of the others. Moreover, because we are
conducting these studies in a species with anatomy and physiology so similar to human beings and with
standard, commercially available clinical instrumentation (OCT/OCT-angiography devices), the results could
rapidly translate to clinical testing and provide beneficial analysis tools for use by clinicians and researchers.